Pazenir® (paclitaxel formulated as albumin bound nanoparticles) 5 mg/ml powder for dispersion for infusion: temporary supply shortage.

Summary

• Increased demand in Europe for albumin-stabilised nanoparticle paclitaxel will lead to temporary supply shortage in some EU markets. This is expected at the beginning of January 2023. [The duration of the supply shortage is market specific – each of the affected markets to include country specific information to reflect local situation]
• Certain European countries will be impacted by this situation, including Austria, Bulgaria, Czech Republic, Denmark, France, Greece, Italy, Netherlands, Portugal, Romania and Spain.
• Production of albumin-stabilised nanoparticle paclitaxel at our manufacturing plant has been significantly ramped up. Furthermore, we are working with health authorities and our supply chain colleagues to assess how allocations can be made across countries.